Loading...
•
Dec 31, 2019
Danaher Q4 2019 Earnings Report
Danaher's Q4 2019 results reflected revenue growth and increased earnings per share.
Key Takeaways
Danaher Corporation reported a 5.5% increase in revenue to $4.9 billion for Q4 2019, with net earnings of $792.9 million, or $1.07 per diluted share. Non-GAAP adjusted diluted net earnings per share were $1.28, representing a 12.5% increase year-over-year. The company achieved 6.0% core revenue growth.
Revenue increased by 5.5% year-over-year to $4.9 billion.
Net earnings were $792.9 million, or $1.07 per diluted share.
Non-GAAP adjusted diluted net earnings per share were $1.28, a 12.5% increase year-over-year.
Core revenue growth was 6.0%.
Danaher
Danaher
Danaher Revenue by Segment
Revenue by Segment
Life Sciences Revenue
CapyFin.comDiagnostics Revenue
CapyFin.com Forward Guidance
The Company anticipates for the first quarter 2020, diluted net earnings per share will be in the range of $0.78 to $0.81 and non-GAAP adjusted diluted net earnings per share will be in the range of $1.06 to $1.09. For the full year 2020, the Company anticipates that diluted net earnings per share will be in the range of $3.96 to $4.06 and non-GAAP adjusted diluted net earnings per share will be $4.80 to $4.90, which assumes non-GAAP core revenue growth of approximately 5.0%.
Positive Outlook
- Diluted net earnings per share for Q1 2020 are expected to be in the range of $0.78 to $0.81.
- Non-GAAP adjusted diluted net earnings per share for Q1 2020 are expected to be in the range of $1.06 to $1.09.
- Diluted net earnings per share for FY 2020 are anticipated to be in the range of $3.96 to $4.06.
- Non-GAAP adjusted diluted net earnings per share for FY 2020 are expected to be $4.80 to $4.90.
- FY 2020 guidance assumes non-GAAP core revenue growth of approximately 5.0%.
Challenges Ahead
- Q1 and FY 2020 estimated results do not include the impact of earnings from the pending GE Biopharma acquisition.
- Uncertainty of regulatory approvals with respect to the GE Biopharma acquisition and the timing or conditionality thereof.
- Parties' ability to satisfy the acquisition agreement conditions and consummate the acquisition of GE Biopharma on the anticipated timetable and terms or at all.
- Danaher's ability to successfully integrate GE Biopharma's operations and employees with Danaher's existing business.
- Ability to realize anticipated financial, tax and operational synergies and benefits.
Revenue & Expenses
Visualization of income flow from segment revenue to net income